Show simple item record

dc.contributor.authorCairns, Lauren M.
dc.contributor.authorRankin, Julia
dc.contributor.authorHamad, Asma
dc.contributor.authorCooper, Nicola
dc.contributor.authorMerrifield, Katrina
dc.contributor.authorJain, Vani
dc.contributor.authorRosser, Elisabeth
dc.contributor.authorRogers, Megan
dc.contributor.authorBuston, Sarah
dc.contributor.authorStopford, Cheryl
dc.contributor.authorJones, Gabriela
dc.contributor.authorLefroy, Henrietta
dc.contributor.authorNémeth, Andrea H.
dc.contributor.authorHolden, Simon
dc.contributor.authorDouglas, Andrew G. L.
dc.date.accessioned2021-08-12T10:39:52Z
dc.date.available2021-08-12T10:39:52Z
dc.date.issued2021-05-07
dc.identifier.citationCairns, L. M. et al. (2021) ‘Genetic testing in motor neuron disease and frontotemporal dementia: a 5-year multicentre evaluation.’, Journal of medical genetics. doi: 10.1136/jmedgenet-2021-107776.
dc.identifier.pmid33963046
dc.identifier.doi10.1136/jmedgenet-2021-107776
dc.identifier.urihttps://rde.dspace-express.com/handle/11287/621887
dc.description.abstractINTRODUCTION: Motor neuron disease (MND) and frontotemporal dementia (FTD) comprise a neurodegenerative disease spectrum. Genetic testing and counselling is complex in MND/FTD owing to incomplete penetrance, variable phenotype and variants of uncertain significance. Affected patients and unaffected relatives are commonly referred to clinical genetics to consider genetic testing. However, no consensus exists regarding how such genetic testing should best be undertaken and on which patients. OBJECTIVE: We sought to ascertain UK clinical genetics testing practice in MND/FTD referrals, with the aim of helping inform guideline development. METHODS: MND/FTD clinical genetics referrals comprising both affected patients and unaffected relatives between 2012 and 2016 were identified and a standardised proforma used to collate data from clinical records. RESULTS: 301 referrals (70 affected, 231 unaffected) were reviewed across 10 genetics centres. Previously identified familial variants were known in 107 cases and 58% subsequently underwent testing (8 of 8 diagnostic and 54 of 99 predictive). The median number of genetic counselling appointments was 2 for diagnostic and 4 for predictive testing. Importantly, application of current UK Genomic Test Directory eligibility criteria would not have resulted in detection of all pathogenic variants observed in this cohort. CONCLUSION: We propose pragmatic MND/FTD genetic testing guidelines based on appropriate genetic counselling.
dc.language.isoeng
dc.publisherBMJ
dc.relation.urlhttps://jmg.bmj.com/lookup/pmidlookup?view=long&pmid=33963046
dc.rights© Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ.
dc.subjectgenetic testing
dc.subjectdementia
dc.subjectmotor neurone disease
dc.subjectneurodegenerative diseases
dc.titleGenetic testing in motor neuron disease and frontotemporal dementia: a 5-year multicentre evaluation.
dc.typeJournal Article
dc.identifier.journalJournal of medical genetics
dc.description.noteRD&E staff can access the full-text of this article by clicking on the 'Additional Link' above and logging in with NHS OpenAthens if prompted.
dc.type.versionPublished
dc.description.admin-notePublished version, accepted version, submitted version


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record